BeiGene to Present at Upcoming Investor Conferences

Rhea-AI Summary

BeiGene, a leading global biotechnology company, has announced its participation in two significant investor conferences. The Guggenheim Oncology Conference is scheduled for February 8, 2023, at 9:35 a.m. ET, followed by the SVB Securities Global Biopharma Conference on February 15, 2023, at 1:40 p.m. ET. Investors can access live webcasts and archived replays through the investors section of BeiGene’s website. The company aims to improve treatment access through innovative oncology medicines and has a diverse pipeline of therapeutics. With over 9,000 employees worldwide, BeiGene is committed to enhancing patient outcomes globally.

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)-- BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in two upcoming investor conferences:

• The Guggenheim Oncology Conference 2023 on Wednesday, February 8, 2023 at 9:35 a.m. ET; and
• The SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 1:40 p.m. ET.

Live webcasts of these events can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com and archived replays will be available for 90 days following the events.

About BeiGene

BeiGene is a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 9,000 colleagues spans five continents, with administrative offices in Cambridge, U.S., & Basel, Switzerland & Beijing, China. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneGlobal.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005204/en/

Investor:

Kevin Mannix

+1 240-410-0129

ir@beigene.com



Media:

Kyle Blankenship

+1 667- 351-5176

media@beigene.com

Source: BeiGene

FAQ

What dates will BeiGene participate in investor conferences in 2023?

BeiGene will participate in the Guggenheim Oncology Conference on February 8, 2023, and the SVB Securities Global Biopharma Conference on February 15, 2023.

What time does the Guggenheim Oncology Conference start for BeiGene?

The Guggenheim Oncology Conference will start at 9:35 a.m. ET on February 8, 2023.

How can investors access the BeiGene conference webcasts?

Investors can access live webcasts of the conferences through the investors section of BeiGene’s website.

How long will the archived replays of BeiGene's conferences be available?

Archived replays of BeiGene's conferences will be available for 90 days following the events.

What is BeiGene's main focus in biotechnology?

BeiGene focuses on developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes for patients worldwide.